Lotte (KRX:004990) subsidiary Lotte Biologics signed a contract with an unnamed Asian biotech firm to manufacture clinical trial materials for an antibody-drug conjugate (ADC), marking the launch of its $100 million ADC production facility at the Syracuse Bio Campus in New York.
The cGMP-compliant plant offers integrated one-stop contract development and manufacturing organization services, from development to commercial-scale manufacturing, Lotte Biologics said Thursday.
Shares of Lotte rose nearly 1% at market close on Friday, April 25.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.